Denali Therapeutics Inc
NASDAQ:DNLI
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
14.96
31.58
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Denali Therapeutics Inc
Wall Street
Price Targets
DNLI Price Targets Summary
Denali Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
DNLI
is 43.62 USD
with a low forecast of 28.28 USD and a high forecast of 94.5 USD.
DNLI Last Price Targets
Denali Therapeutics Inc
The latest public price target was made on Nov 1, 2024 by
Michael Yee
from
Jefferies
,
who expects
DNLI
stock to
rise by 110%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Michael Yee
Jefferies
|
45
USD
Upside 110% |
1 month ago
Nov 1, 2024
|
Denali Therapeutics Inc. (DNLI) PT Raised to $45 at Jefferies
StreetInsider
|
|
Thomas Shrader
BTIG
|
35
USD
Upside 63% |
2 months ago
Oct 14, 2024
|
BTIG Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
StreetInsider
|
Tazeen Ahmad
Bank of America Securities
|
29
USD
Upside 35% |
3 months ago
Sep 4, 2024
|
Denali Therapeutics price target raised to $29 from $25 at BofA
TheFly
|
Salveen Richter
Goldman Sachs
|
46
USD
Upside 114% |
3 months ago
Sep 3, 2024
|
Goldman Sachs Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
StreetInsider
|
|
Marank Mamtani
B.Riley Financial
|
33
USD
Upside 54% |
3 months ago
Sep 3, 2024
|
B.Riley Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
StreetInsider
|
Paul Mattels
Stifel Nicolaus
|
22
USD
Upside 3% |
3 months ago
Sep 3, 2024
|
Stifel Reiterates Hold Rating on Denali Therapeutics Inc. (DNLI)
StreetInsider
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is DNLI's stock price target?
Price Target
43.62
USD
According to Wall Street analysts, the average 1-year price target for
DNLI
is 43.62 USD
with a low forecast of 28.28 USD and a high forecast of 94.5 USD.
What is Denali Therapeutics Inc's Revenue forecast?
Projected CAGR
5%
The
compound annual growth rate
of Denali Therapeutics Inc's revenue for the next 4 years is
5%.
You don't have any saved screeners yet
